Eligible patients pay $0 per prescription*

TOS-PP SIGN UP
*Restrictions apply.

What is Zembrace® SymTouch®

Zembrace® SymTouch® is a prescription medicine used to treat acute migraine headaches with or without aura in adults 18 years of age and older who have been diagnosed with migraine.

Zembrace® SymTouch® is not used to treat other types of headaches such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura) migraines.

Zembrace® SymTouch® is not used to prevent or decrease the number of migraines you have.

Fast and powerful

In as little as 10 minutes, you may get migraine relief (17% for sumatriptan 3 mg vs. 5% for placebo). One study showed that 60% of people experienced pain relief within 2 hours of use (vs. 21% for placebo).1

The most common side effects of Zembrace® SymTouch® include pain and redness at your injection site; tingling or numbness in your fingers or toes; dizziness; warm, hot burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy or tired.1

Simple

  • Smallest needle in a sumatriptan pen2 (auto-injector)
  • Simple, two-step injection process1,3
  • No refrigeration needed*

Pay $0 per prescription*

Eligible commercially insured patients pay $0 per prescription,* regardless of coverage.

Savings made simple

You can save on Zembrace® SymTouch® with the Platinum Pass® savings card.*

Get Savings

*Restrictions apply. Maximum of eight single-use injections per month. Medicare, Medicaid, and other state and federal health care program patients are not eligible.

Instructions for Use

Learn how to use the Zembrace® SymTouch® pen.

Watch video

References:

  1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: July 2019.
  2. Data on file. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
  3. Brand-Schieber E, Munjal S, Kumar R, et al. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Med Devices (Auckl). 2016;9:131-137.